{
    "prompt": "1. Protocol SummaryMANDATORY SPONSOR INPUTS FOR STUDY PROTOCOL GENERATION\nSponsor Name FADOI /BMS/PFIZER\nStudy Acronym (if available):  CARAVAGGIO Study\nTested IMP :Apixaban\nComparative drug: Dalteparin\nStudy Type Interventional\nSe Study Type = Interventional:\nInterventional Study Phase Phase IIIb\nStudy Design International, multicenter, Prospective Randomized Open Blinded End-point (PROBE), where both patients and investigators are aware of the treatment assignments, but the outcome assessment is blindedactive-controlled, event-driven, Phase IIIB clinical study comparing the efficacy and safety of Apixaban to the SOC Dalteparin in for the treatment of venous thromboembolism in patients with cancer.\nAim of the study: The aim of this study is to assess whether oral apixaban is non-inferior to the subcutaneous low molecular weight (LMWH) dalteparin for the treatment of newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer.\nTarget Disease: VTE (DVT/PE) in cancer patients\nType of Randomization: Patients will be randomized on a 1:1 basis (permuted blocks of four) to receive either apixaban or dalteparin in an open-label fashion.\nRandomization should be centralized and stratified by:\n1) symptomatic vs. unsuspected VTE\n2) active cancer vs. history of cancer\nTested drugs and dosages \nApixaban group: orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)\nDalteparin group: subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months (total period of treatment: six months). The maximum daily dose allowed for dalteparin is 18,000IU.\nApixaban 5mg will be supplied by the Promoter as film-coated tablets.\nDalteparin will be supplied by the Promoter as single-use pre-filled syringes.\nStudy Scheduled Patient’s Visits\nThe study should foresee the following scheduled visits: at enrollment, at 4 weeks, at 3 months, at 6 months, at the end of study treatment whenever it occurs, and at 7 months from randomization.\nAdditional visits will be performed if new symptoms and/or signs of VTE or major bleeding develop. A clinical examination and objective tests will be performed if the patient develops symptoms or signs suggestive of recurrent VTE.\nStudy Objectives \nPrimary efficacy outcome:\nobjectively confirmed recurrent VTE occurring during the study period, that means the composite of:\n• proximal DVT of the lower limbs (symptomatic or unsuspected)\n• DVT of the upper limb (symptomatic)\n• PE (symptomatic or unsuspected)\nSecondary efficacy outcomes:\n• the individual components of the primary efficacy outcome;\n• symptomatic recurrence of VTE;\n• all cause death;\n• the composite of primary efficacy outcome plus major bleeding;\n• the composite of primary efficacy outcome plus major bleeding plus all cause death;\n• the composite of primary efficacy outcome plus all cause death;\n• any major cardiovascular event, fatal or non-fatal (including acute myocardial infarction or ischemic stroke);\n• all venous thromboembolic events (including splanchnic vein thrombosis and cerebral vein thrombosis);\n• Quality of life (QoL) according to Anti-Clot Treatment Scale (ACTS) \nSafety Study Outcomes:\nPrimary safety outcome is major bleeding, defined (as per ISTH guidelines), as acute clinically overt bleeding associated with one or more of the following:\n• decrease in hemoglobin of 2 g/dl (1.2 mmol/L) or more;\n• transfusion of 2 or more units of packed red blood cells;\n• bleeding that occurs in at least one critical site [intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal];\n• bleeding that is fatal;\n• bleeding that necessitates acute surgical intervention\nSecondary safety outcomes include:\n• Clinically relevant non-major bleeding event defined as acute clinically overt bleeding that does not meet the criteria for major and consists of:\n• any bleeding compromising hemodynamics;\n• spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause;\n• intramuscular hematoma documented by ultrasonography;\n• epistaxis or gingival bleeding requiring tamponade or other medical intervention or bleeding from venipuncture for >5 minutes;\n• hematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures;\n• hemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention;\n• or any other bleeding considered to have clinical consequences for a patient such as medical intervention,\nthe need for unscheduled contact (visit or telephone call) with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.\n• Clinically relevant bleeding defined as the composite of major and clinically relevant non-major bleeding\n• Permanent early discontinuation of study drug due to safety reasons\nMaximum Sample Size for each arm\nLess than 600 patients for each treatment group\nRecommended Inclusion Criteria\nAge > 18 years\nBoth Genders\nSigned Informed Consent\nConsecutive patients with a newly diagnosed, objectively\nconfirmed:\n• symptomatic or unsuspected, proximal lower-limb DVT\nor\n• symptomatic PE or\n• unsuspected PE in a segmental or more proximal pulmonary artery.\nAny type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or known intracerebral metastases and acute leukemia) that meets at least one of the\nfollowing:\n• Active cancer defined as diagnosis of cancer within six months before the study inclusion, or receiving treatment for cancer at the time of inclusion or any treatment for cancer during 6 months prior to randomization, or recurrent locally advanced or metastatic cancer.\n• Cancer diagnosed within 2 years before the study inclusion (history of cancer).\nRecommended Exclusion Criteria\nage <18 years\nECOG Performance Status III or IV;\nlife expectancy of less than 6 months;\nrelated to anticoagulant treatment:\nadministration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization;\n3 or more doses of a vitamin K antagonist before randomization;\nthrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;\n indication for anticoagulant treatment for a disease other than the index VTE episode;\nconcomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein ;\nrelated to bleeding risk:\nconcomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;\nactive bleeding or high risk of bleeding contraindicating anticoagulant treatment\nrecent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery\n hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x109/L or history of heparin-induced thrombocytopenia;\ncreatinine clearance < 30 ml /min based on the Cockcroft Gault equation;\nacute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;\nuncontrolled hypertension (systolic BP> 180 mm Hg or diastolic BP > 100 mm Hg despite antihypertensive treatment);\nstandard criteria:\n bacterial endocarditis;\nhypersensitivity to the study drugs or to any of their excipients;\npatients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system.\nwomen of childbearing potential (WOCBP) who do not practice a medically accepted highly effective contraception during the trial and one month beyond. Highly effective contraception methods are:\na. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation\nb. progestogen-only hormonal contraception associated with inhibition of ovulation\nc. intrauterine device (IUD)\nd. intrauterine hormone-releasing system (IUS)\ne. bilateral tubal occlusion\nf. vasectomized partner\ng. sexual abstinence ;\npregnancy, or breast feeding\nany condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study.\n",
    "output": "# 1. Protocol Summary\n\n\n\n=== TABLE 1 ===\n| Objectives <br> Endpoints |  |\n| --- | --- |\n| Primary |  |\n| - To assess the non-inferiority of oral apixaban compared to subcutaneous low <br> molecular weight heparin (LMWH) dalteparin for the treatment of newly <br> diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism <br> (PE) in patients with cancer. <br> - |  |\n| Secondary |  |\n| - To compare the rates of the composite of major and clinically relevant non- <br> major (CRNM) bleeding, and all bleeding events between the apixaban and <br> dalteparin groups. <br> - To assess the incidence of major bleeding (MB) and clinically relevant non- <br> major bleeding (CRNMB). <br> - To evaluate rates of major bleeding in patient subgroups. <br> - To compare the incidence of the Major Venous Thromboembolism (VTE) <br> endpoint, a composite of proximal deep vein thrombosis (DVT), non-fatal <br> pulmonary embolism (PE), and VTE-related death, between apixaban and <br> dalteparin. <br> - To evaluate the efficacy of apixaban versus dalteparin in patient subgroups <br> defined by cancer type and whether the VTE was incidental versus <br> symptomatic. <br> - To evaluate the individual components of the primary efficacy outcome. <br> - To evaluate symptomatic recurrence of VTE. <br> - To evaluate all-cause death. <br> - To evaluate the composite of the primary efficacy outcome plus major <br> bleeding. <br> - To evaluate the composite of the primary efficacy outcome plus all-cause <br> death. <br> - To evaluate the composite of the primary efficacy outcome plus major bleeding <br> plus all-cause death. <br> - To evaluate any major cardiovascular event, fatal or non-fatal, including acute <br> myocardial infarction or ischemic stroke. <br> - To evaluate all venous thromboembolic events, including splanchnic vein <br> thrombosis and cerebral vein thrombosis. <br> - To evaluate permanent early discontinuation of the study drug due to safety <br> reasons. <br> - To assess Quality of Life (QoL) according to the Anti-Clot Treatment Scale <br> (ACTS). <br> - |  |\n\n=== TABLE 2 ===\n| Objectives <br> Endpoints |  |\n| --- | --- |\n| - To conduct analyses and report on patient subgroups defined by cancer type, <br> cancer treatment, and incidental versus symptomatic VTE. |  |\n\n=== TABLE 3 ===\n| Procedure <br> Screening <br> (up to <br> specified <br> days before <br> Day 1) | Intervention Period (6 Months) |  |  |  |  |  |  |  |  | E/ <br> D <br> Follow-up (Month <br> 7 from <br> randomization) | Notes |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  | – <br> 1 <br> 1 | 2 <br> 3 | 4 <br> 5 | 6 <br> 7 | 8 |  |  | E/D = Early Discontinuation |  |  |  |\n| Informed consent <br> X |  |  |  |  |  |  |  |  |  |  |  |  |\n| Inclusion and <br> exclusion criteria <br> X |  |  |  |  |  |  |  |  |  |  |  | Recheck clinical status <br> before randomization and/or <br> first dose of investigational <br> intervention. |\n| Demography <br> X |  |  |  |  |  |  |  |  |  |  |  |  |\n| Full physical <br> examination <br> including height and <br> weight <br> X |  |  |  |  |  |  |  |  |  | X <br> X |  |  |\n| Medical history <br> (includes substance <br> use and family <br> history of premature <br> CV disease) <br> X |  |  |  |  |  |  |  |  |  |  |  |  |\n\n=== TABLE 4 ===\n| Procedure <br> Screening <br> (up to <br> specified <br> days before <br> Day 1) | Intervention Period (6 Months) |  |  |  |  |  |  |  |  | E/ <br> D <br> Follow-up (Month <br> 7 from <br> randomization) | Notes |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  | – <br> 1 <br> 1 | 2 <br> 3 | 4 <br> 5 | 6 <br> 7 | 8 |  |  | E/D = Early Discontinuation |  |  |  |  |\n| Current medical <br> conditions <br> X |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| Pregnancy test (CBP <br> participants only) <br> X |  |  |  |  |  |  |  |  |  |  |  | Refer to Section 8.3.5 <br> Pregnancy Testing for <br> instruction on timepoints. |  |\n| HIV, Hepatitis B and C <br> screening |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| Laboratory tests <br> (include liver <br> chemistries) <br> X |  |  |  |  |  |  |  |  |  |  |  | Includes Hemoglobin, <br> platelet count, creatinine <br> clearance, liver function <br> tests. Repeat testing for <br> clinically significant <br> abnormal values until <br> normalization. |  |\n| 12-lead ECG <br> X |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\n=== TABLE 5 ===\n| Procedure <br> Screening <br> (up to <br> specified <br> days before <br> Day 1) | Intervention Period (6 Months) |  |  |  |  |  |  |  |  |  |  | E/ <br> D <br> Follow-up (Month <br> 7 from <br> randomization) | Notes |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  | – <br> 1 <br> 1 | 2 <br> 3 | 4 <br> 5 | 6 <br> 7 | 8 |  |  |  |  | E/D = Early Discontinuation |  |  |  |  |\n| Vital signs <br> X |  | X |  |  |  |  |  |  |  |  | X <br> X | Performed at each <br> visit. |  |  |  |\n| Randomization (if <br> applicable) |  | X |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| Genetic sample <br> X |  |  |  |  |  |  |  |  |  |  |  |  |  | Optional participation with <br> separate consent. |  |\n| Study intervention |  |  | X <br> X | X <br> X | X <br> X | X <br> X | X <br> X |  |  | Administered for 6 months. <br> Apixaban: 10 mg BID for first <br> 7 days, then 5 mg BID. <br> Dalteparin: 200 IU/kg daily <br> for first month, then 150 IU/ <br> kg daily. |  |  |  |  |  |\n| AE review |  |  | X |  |  |  |  |  |  |  | X <br> X | X <br> X | Monitored continuously from <br> intervention start until the <br> follow-up visit. |  |  |\n\n=== TABLE 6 ===\n| Procedure <br> Screening <br> (up to <br> specified <br> days before <br> Day 1) | Intervention Period (6 Months) |  |  |  |  |  |  |  |  |  |  | E/ <br> D <br> Follow-up (Month <br> 7 from <br> randomization) | Notes |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  | – <br> 1 <br> 1 | 2 <br> 3 | 4 <br> 5 | 6 <br> 7 | 8 |  |  |  |  | E/D = Early Discontinuation |  |  |  |  |\n| Solicited <br> administration-site <br> events (if applicable) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| Unsolicited AEs (if <br> applicable) |  |  | X |  |  |  |  |  |  |  | X <br> X | X <br> X | Monitored continuously from <br> intervention start until the <br> follow-up visit. |  |  |\n| SAE review |  |  | X |  |  |  |  |  |  |  | X <br> X | X <br> X | Monitored continuously from <br> intervention start until the <br> follow-up visit. |  |  |\n| Device deficiencies (if <br> applicable) |  |  | X <br> X | X <br> X | X <br> X | X <br> X | X <br> X |  |  | Monitored throughout the 6- <br> month intervention period for <br> dalteparin pre-filled syringes. |  |  |  |  |  |\n| Concomitant <br> medication review <br> X |  | X |  |  |  |  |  |  |  | X <br> X | X <br> X | Reviewed at screening and <br> all subsequent visits. |  |  |  |\n\n=== TABLE 7 ===\n| Procedure <br> Screening <br> (up to <br> specified <br> days before <br> Day 1) | Intervention Period (6 Months) |  |  |  |  |  |  |  |  |  |  | E/ <br> D <br> Follow-up (Month <br> 7 from <br> randomization) | Notes |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  | – <br> 1 <br> 1 | 2 <br> 3 | 4 <br> 5 | 6 <br> 7 | 8 |  |  |  |  | E/D = Early Discontinuation |  |  |\n| Study-specific <br> assessments (e.g., <br> PK, efficacy) |  |  |  |  |  |  |  |  |  |  | X <br> X | X <br> X | Efficacy events (VTE, death) <br> monitored throughout the 6- <br> month intervention period. <br> Final efficacy assessment at <br> Month 6. |\n| PRO assessments <br> X |  |  |  |  |  |  |  |  |  |  | X <br> X | X <br> Quality of Life (ACTS) <br> assessed. Schedule not <br> specified. |  |",
    "context": "MANDATORY SPONSOR INPUTS FOR STUDY PROTOCOL GENERATION\nSponsor Name FADOI /BMS/PFIZER\nStudy Acronym (if available):  CARAVAGGIO Study\nTested IMP :Apixaban\nComparative drug: Dalteparin\nStudy Type Interventional\nSe Study Type = Interventional:\nInterventional Study Phase Phase IIIb\nStudy Design International, multicenter, Prospective Randomized Open Blinded End-point (PROBE), where both patients and investigators are aware of the treatment assignments, but the outcome assessment is blindedactive-controlled, event-driven, Phase IIIB clinical study comparing the efficacy and safety of Apixaban to the SOC Dalteparin in for the treatment of venous thromboembolism in patients with cancer.\nAim of the study: The aim of this study is to assess whether oral apixaban is non-inferior to the subcutaneous low molecular weight (LMWH) dalteparin for the treatment of newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer.\nTarget Disease: VTE (DVT/PE) in cancer patients\nType of Randomization: Patients will be randomized on a 1:1 basis (permuted blocks of four) to receive either apixaban or dalteparin in an open-label fashion.\nRandomization should be centralized and stratified by:\n1) symptomatic vs. unsuspected VTE\n2) active cancer vs. history of cancer\nTested drugs and dosages \nApixaban group: orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)\nDalteparin group: subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months (total period of treatment: six months). The maximum daily dose allowed for dalteparin is 18,000IU.\nApixaban 5mg will be supplied by the Promoter as film-coated tablets.\nDalteparin will be supplied by the Promoter as single-use pre-filled syringes.\nStudy Scheduled Patient’s Visits\nThe study should foresee the following scheduled visits: at enrollment, at 4 weeks, at 3 months, at 6 months, at the end of study treatment whenever it occurs, and at 7 months from randomization.\nAdditional visits will be performed if new symptoms and/or signs of VTE or major bleeding develop. A clinical examination and objective tests will be performed if the patient develops symptoms or signs suggestive of recurrent VTE.\nStudy Objectives \nPrimary efficacy outcome:\nobjectively confirmed recurrent VTE occurring during the study period, that means the composite of:\n• proximal DVT of the lower limbs (symptomatic or unsuspected)\n• DVT of the upper limb (symptomatic)\n• PE (symptomatic or unsuspected)\nSecondary efficacy outcomes:\n• the individual components of the primary efficacy outcome;\n• symptomatic recurrence of VTE;\n• all cause death;\n• the composite of primary efficacy outcome plus major bleeding;\n• the composite of primary efficacy outcome plus major bleeding plus all cause death;\n• the composite of primary efficacy outcome plus all cause death;\n• any major cardiovascular event, fatal or non-fatal (including acute myocardial infarction or ischemic stroke);\n• all venous thromboembolic events (including splanchnic vein thrombosis and cerebral vein thrombosis);\n• Quality of life (QoL) according to Anti-Clot Treatment Scale (ACTS) \nSafety Study Outcomes:\nPrimary safety outcome is major bleeding, defined (as per ISTH guidelines), as acute clinically overt bleeding associated with one or more of the following:\n• decrease in hemoglobin of 2 g/dl (1.2 mmol/L) or more;\n• transfusion of 2 or more units of packed red blood cells;\n• bleeding that occurs in at least one critical site [intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal];\n• bleeding that is fatal;\n• bleeding that necessitates acute surgical intervention\nSecondary safety outcomes include:\n• Clinically relevant non-major bleeding event defined as acute clinically overt bleeding that does not meet the criteria for major and consists of:\n• any bleeding compromising hemodynamics;\n• spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause;\n• intramuscular hematoma documented by ultrasonography;\n• epistaxis or gingival bleeding requiring tamponade or other medical intervention or bleeding from venipuncture for >5 minutes;\n• hematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures;\n• hemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention;\n• or any other bleeding considered to have clinical consequences for a patient such as medical intervention,\nthe need for unscheduled contact (visit or telephone call) with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.\n• Clinically relevant bleeding defined as the composite of major and clinically relevant non-major bleeding\n• Permanent early discontinuation of study drug due to safety reasons\nMaximum Sample Size for each arm\nLess than 600 patients for each treatment group\nRecommended Inclusion Criteria\nAge > 18 years\nBoth Genders\nSigned Informed Consent\nConsecutive patients with a newly diagnosed, objectively\nconfirmed:\n• symptomatic or unsuspected, proximal lower-limb DVT\nor\n• symptomatic PE or\n• unsuspected PE in a segmental or more proximal pulmonary artery.\nAny type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or known intracerebral metastases and acute leukemia) that meets at least one of the\nfollowing:\n• Active cancer defined as diagnosis of cancer within six months before the study inclusion, or receiving treatment for cancer at the time of inclusion or any treatment for cancer during 6 months prior to randomization, or recurrent locally advanced or metastatic cancer.\n• Cancer diagnosed within 2 years before the study inclusion (history of cancer).\nRecommended Exclusion Criteria\nage <18 years\nECOG Performance Status III or IV;\nlife expectancy of less than 6 months;\nrelated to anticoagulant treatment:\nadministration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization;\n3 or more doses of a vitamin K antagonist before randomization;\nthrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;\n indication for anticoagulant treatment for a disease other than the index VTE episode;\nconcomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein ;\nrelated to bleeding risk:\nconcomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;\nactive bleeding or high risk of bleeding contraindicating anticoagulant treatment\nrecent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery\n hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x109/L or history of heparin-induced thrombocytopenia;\ncreatinine clearance < 30 ml /min based on the Cockcroft Gault equation;\nacute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;\nuncontrolled hypertension (systolic BP> 180 mm Hg or diastolic BP > 100 mm Hg despite antihypertensive treatment);\nstandard criteria:\n bacterial endocarditis;\nhypersensitivity to the study drugs or to any of their excipients;\npatients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system.\nwomen of childbearing potential (WOCBP) who do not practice a medically accepted highly effective contraception during the trial and one month beyond. Highly effective contraception methods are:\na. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation\nb. progestogen-only hormonal contraception associated with inhibition of ovulation\nc. intrauterine device (IUD)\nd. intrauterine hormone-releasing system (IUS)\ne. bilateral tubal occlusion\nf. vasectomized partner\ng. sexual abstinence ;\npregnancy, or breast feeding\nany condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study.\n"
}